Phase II Study of Dual Targeting of BCR-ABL1 by Adding the Allosteric Inhibitor ABL001 in Patients With Chronic Myeloid Leukemia (CML) and Minimal Residual Disease (MRD) While on Therapy With Tyrosine Kinase Inhibitors
Latest Information Update: 28 Mar 2025
At a glance
- Drugs Asciminib (Primary) ; Dasatinib; Nilotinib
- Indications Chronic myeloid leukaemia
- Focus Therapeutic Use
Most Recent Events
- 25 Mar 2025 Status changed from active, no longer recruiting to discontinued, because of participation lesser than 75%, however the study was administratively complete.
- 10 Aug 2023 Status changed from recruiting to active, no longer recruiting.
- 15 Jun 2023 Early results presented at the 28th Congress of the European Haematology Association.